secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2022-11-25T23:59:59+00:00
Accession:  0001213900-22-075271
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 3.01, 3.03, 5.03, 5.08, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity receives Nasdaq delisting notice, issues secured notes, creates Series B preferred with super-voting rights
--------------------------------------------------------------------------------

- Received Nasdaq deficiency notice for bid price below $1.00 for 30 consecutive days; 180-day compliance period until May 22, 2023.
- Entered secured note purchase agreement with 3i LP: $350K new loan, $1.67M to pay conversion floor amounts, and $650K upon S-1 filing.
- Created Series B Preferred Stock with 400 votes/share, votes only on reverse stock split, share increase, and adjournment proposals.
- Declared dividend of Series B Preferred to holders of common and Series A preferred as of Dec 5, 2022.
- Terminated 2022 annual meeting; 2023 annual meeting set for Jan 16, 2023, record date Dec 6, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390022075271/0001213900-22-075271-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390022075271/ea169266-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-075271

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer